Celgene joins the heavyweight partner club collaborating with Nimbus
The Nimbus Therapeutics team has a good track record for finding the ideal partner.
There was Gilead $GILD on NASH — with a massive $600 million in upfront and near-term cash — and Genentech stepped in to grab rights to an IRAK4 cancer program from the computational chemistry experts at Nimbus. And now you can add Celgene $CELG, which is tying up with Nimbus on two new therapeutic approaches for its growing inflammation/immunology pipeline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.